Literature DB >> 3344444

Psychosocial aspects of head and neck cancer.

W Breitbart1, J Holland.   

Abstract

The major psychosocial issues in managing the patient with a head and neck tumor are dealing with the emotional reactions to structural and functional deficits, recognizing and treating preexisting personality problems, especially those related to alcohol and tobacco abuse, which frequently complicate their treatment course. These factors influence the rehabilitation process which should begin in the preoperative period with careful attention to psychologic and social assessment and psychiatric evaluation; if an alcoholic history is elicited. Important continuity in rehabilitation can be accomplished by contact with the rehabilitative team members before surgery, preoperative chemotherapy or radiation. Attention to appropriate adaptation to facial prostheses and dealing early with communication disorders requires a specialized staff and a rehabilitative team which can call on a range of skills including a psychiatric consultant. While the ordeal of the head and neck cancer patient is psychologically difficult and challenging, most patients are able, with the proper help, to resume full and productive lives.

Entities:  

Mesh:

Year:  1988        PMID: 3344444

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  16 in total

1.  Psychometric testing of the Impact of Event Scale-Chinese Version (IES-C) in oral cancer patients in Taiwan.

Authors:  Shu-Ching Chen; Yeur-Hur Lai; Chun-Ta Liao; Chia-Chin Lin
Journal:  Support Care Cancer       Date:  2005-02-17       Impact factor: 3.603

Review 2.  Intensive nutritional care for patients treated with radiotherapy in head and neck cancer: a randomized study and meta-analysis.

Authors:  Lise-Marie Roussel; Emmanuel Micault; Damien Peyronnet; David Blanchard; Séverine Guarnieri; Olivier Choussy; Bernard Géry; Arnaud Béquignon; Corinne Joubert; Jean-Jacques Parienti; Emmanuel Babin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-27       Impact factor: 2.503

Review 3.  A systematic review of head and neck cancer quality of life assessment instruments.

Authors:  Bukola Ojo; Eric M Genden; Marita S Teng; Kathrin Milbury; Krzysztof J Misiukiewicz; Hoda Badr
Journal:  Oral Oncol       Date:  2012-04-21       Impact factor: 5.337

4.  Longitudinal oncology registry of head and neck carcinoma (LORHAN): initial supportive care findings.

Authors:  Barbara A Murphy; Amy Chen; Walter J Curran; Adam S Garden; Paul M Harari; Stuart J Wong; K Kian Ang
Journal:  Support Care Cancer       Date:  2009-03-05       Impact factor: 3.603

Review 5.  Assessing quality of life in head and neck cancer.

Authors:  C C Gotay; T D Moore
Journal:  Qual Life Res       Date:  1992-02       Impact factor: 4.147

6.  Coping with oral cancer: the impact of health and disease-related personality traits.

Authors:  Madiha Rana; Nils-Claudius Gellrich; Franziska Czens; Anastasios Kanatas; Majeed Rana
Journal:  Support Care Cancer       Date:  2014-06-05       Impact factor: 3.603

7.  A qualitative study of head and neck cancer.

Authors:  R J Moore; R M Chamberlain; F R Khuri
Journal:  Support Care Cancer       Date:  2004-04-03       Impact factor: 3.603

8.  A survey of consultants treating upper aerodigestive tract cancer in the UK.

Authors:  D M Edwards; N W Johnson; D Cooper; K A Warnakulasuriya
Journal:  Ann R Coll Surg Engl       Date:  1998-07       Impact factor: 1.891

9.  Quality of life in patients treated for cancer of the oral cavity requiring reconstruction: a prospective study.

Authors:  A Bolzoni Villaret; J Cappiello; C Piazza; B Pedruzzi; P Nicolai
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-06       Impact factor: 2.124

10.  Two-year quality of life after free flap reconstruction in tumor-site discrepancy among Taiwanese with moderately advanced oral squamous cell carcinoma.

Authors:  Kao-Ping Chang; Chung-Sheng Lai; Tung-Ying Hsieh; Yi-Chia Wu; Chih-Hau Chang
Journal:  World J Surg Oncol       Date:  2012-07-13       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.